Safety and efficacy of everolimus-eluting bioresorbable vascular scaffold for cardiac allograft vasculopathy (CART)
ConclusionsBRS-based PCI for the treatment of CAV is feasible and safe, with an ISSR incidence similar to what reported in retrospective studies with drug-eluting stents.Graphical abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Angiography | Angioplasty | Bone Graft | Cardiology | Coronary Angioplasty | Heart | Heart Transplant | Palliative | Percutaneous Coronary Intervention | Study | Transplants